Summary: Isoniazid (INH) is a first-line drug for tuberculosis control; the side effects of INH are thought to be associated with its metabolism, and this study was designed to globally characterize isoniazid metabolism. Metabolomic strategies were used to profile isoniazid metabolism in humans. Eight known and seven novel INH metabolites and hydrazones were identified in human urine. The novel products included two hydroxylated INH metabolites and five hydrazones. The two novel metabolites were determined as 2-oxo-1,2-dihydro-pyridine-4-carbohydrazide and isoniazid N-oxide. Five novel hydrazones were produced by condensation of isoniazid with keto acids that are intermediates in the metabolism of essential amino acids, namely, leucine and/or isoleucine, lysine, tyrosine, tryptophan, and phenylalanine. This study enhances our knowledge of isoniazid metabolism and disposition and may offer new avenues for investigating INHinduced toxicity.
Introduction
Isoniazid ¤INH¥ is a highly effective anti-tuberculosis drug; 1¥ however, INH frequently causes toxicity that includes liver injury, peripheral neuropathy, mild central nervous system effects, and sideroblastic anemia. 2®4¥ The detailed mechanism of INH toxicity remains unknown. Hepatotoxicity of INH is thought to be mediated by the nitrogen-containing group in its chemical structure, as it is metabolized in the liver and converted into a reactive metabolite that causes hepatitis.
5®7¥ INH-induced peripheral neuropathy, central nervous system effects, and sideroblastic anemia are thought to be associated with the effect of INH on pyridoxine ¤vitamin B6¥ homeostasis because INH may condense with pyridoxine to form hydrazone.
8,9¥
Because of the potential role of metabolism in INH toxicity, INH metabolism has been studied extensively. In the early 1950s, three metabolites of INH were identified: isonicotinic acid ¤INA¥, hydrazine ¤HZ¥, and ammonia ¤NH 3 ¥.
10,11¥ Soon after, isonicotinoyl glycine and acetylisoniazid ¤AcINH¥ were also discovered. 12®14¥ The advent of chromatographic techniques, radiochemical methods, and mass spectrometry ¤MS¥ enabled researchers to identify additional INH metabolites, such as acetylhydrazine ¤AcHZ¥ and N,N 1 -diacetylhydrazine ¤DiAcHZ¥, and hydrazone derivatives of pyruvic and AE-ketoglutaric acids.
15®19¥
To achieve a global picture of INH metabolism and disposition, we revisited INH metabolism in humans using a metabolomic approach. Metabolomics combines highresolution molecular spectroscopy, mainly MS or nuclear magnetic resonance ¤NMR¥ spectrometry, with multivariate data analysis for the rapid and systematic profiling of small molecular metabolites found in an organism. 20¥ We took advantage of the speed and resolving power of ultraperformance liquid chromatography ¤UPLC¥ and the accurate mass determination of time-of-flight mass spec-trometry ¤TOFMS¥ to monitor the metabolism of INH. Seven novel and eight known INH metabolites and hydrazones were identified in human urine.
Methods
Chemicals and reagents: INH, m-chloroperbenzoic acid, keto acids, and DMSO-d 6 were purchased from SigmaAldrich ¤St. Louis, MO¥. 2-Oxo-1,2-dihydro-pyridine-4-carbohydrazide ¤metabolite X¥ was purchased from Shanghai Yuanding Chem. Sci. & Tech. Co. Ltd. ¤Shanghai, China¥. All solvents for liquid chromatography and MS were of the highest grade commercially available. Novel hydrazones were prepared by condensation of keto acids with INH.
Human subjects, treatment, and sample preparation: Six healthy subjects ¤Chinese, 3 men and 3 women¥, aged between 30 and 45 years, were recruited for this study. The research followed the tenets of the Declaration of Helsinki promulgated in 1964 and was approved by the Ethics Committee of Zhengzhou University. All participants provided written informed consent. None of the subjects had a history of significant medical illness and none had taken any drug for at least two weeks prior to and during the study. Their health status was judged on the basis of a physical examination and a blood screen, including a complete blood count, liver function test, urine analysis, and electrocardiogram performed prior to the study. Two urine samples per subject were collected. A control urine sample was collected at >8:00 A.M. on the day of the study. At >8:00 P.M., each subject received a single oral dose of 300 mg INH with 200 ml water. At >8:00 A.M. the next day, a second urine sample was collected from each subject. Urine samples were prepared by mixing 80 µL of urine with 320 µL of 50% acetonitrile and centrifuging at 20,000 g for 10 min. Next, 100 µL of each supernatant was transferred to an autosampler vial for analysis. Because some INH metabolites, such as HZ and AcHZ, are undetectable by UPLC-TOFMS, we derivatized the sample using m-anisaldehyde ¤MA¥. MA can readily react with the hydrazine to form the hydrazone, which will be detected by UPLC-TOFMS. A total of 200 µL of each supernatant was transferred into a new Eppendorf vial, followed by addition of MA ¤final concentration of 3 mM¥ and formic acid ¤final concentration of 1.0 mM¥. Following incubation at 37ôC for 40 min, 100 µL of each sample was transferred into an autosampler vial. Five microliters was injected into a system combining UPLC and TOFMS for metabolite analysis.
INH metabolism in vitro: Incubations were conducted in 1' phosphate-buffered saline ¤PBS, pH 7.4¥, containing 50 µM INH, 0.1 mg human liver microsomes or 2 pmol of each cDNA-expressed human CYP450 enzyme ¤control, CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4¥ in a final volume of 190 µL. CYP450 activity was verified using relatively specific substrates and inhibitors ¤data not shown¥. After 5 min of pre-incubation at 37ôC, the reaction was initiated by the addition of 10 µL of 20 mM NADPH ¤final concentration 1.0 mM¥ and was allowed to continue for 30 min with gentle shaking. Incubations in the absence of NADPH were used as controls. Incubations were terminated by adding 200 µL of acetonitrile and vortexing for 1 min and centrifuging at 20,000 g for 10 min. Each supernatant was transferred to an autosampler vial, and 5.0 µL was injected into the UPLC-TOFMS system for metabolite analysis. All the incubations were performed in duplicate.
Synthesis of isoniazid N-oxide ¤metabolite XI¥ and its hydrazone derivative:
21¥
A solution of mchloroperbenzoic acid ¤293 mg, 1.2 mmol, 70% purity¥ in CHCl 3 ¤2 ml¥ was added gradually to an ice-cooled, stirred solution of isoniazid ¤137 mg, 1.0 mmol¥ in CHCl 3 ¤3.0 ml¥. The resulting mixture was stirred for 2 h at room temperature. After removal of the solvent under reduced pressure, the residue was dissolved in CHCN 3 /H 2 O ¤1:1, 5.0 ml¥, followed by addition of m-anisaldehyde ¤272 mg, 2.0 mmol¥ and formic acid ¤10 µL¥. The reaction mixture was incubated at 37ôC for 30 min, diluted, and injected into the UPLC-TOFMS system to confirm the structure of metabolite XI.
Synthesis of novel hydrazones ¤XII®XVI¥:
22¥ INH ¤274 mg, 2 mmol¥, the appropriate keto acid ¤2 mmol¥, and ethanol ¤4.0 ml¥ were added to a 50-ml round flask equipped with a cooler condenser. Then, 20 µL of formic acid was added to the reaction system and the resulting mixture was stirred and heated to reflux on a water bath. After 2 h, the mixture was cooled to room temperature, and the resulting solid product was separated from the solution by suction filtration. The solid was washed twice with water ¤15 ml¥ and twice with ethanol ¤10 ml¥. The products were dried under high vacuum and used for structural confirmation. Reaction with 4-methyl-2-oxopentanoic acid: XIIa was obtained as a white powder in 66% yield ¤328 mg¥; UPLC-TOFMS analysis: A 100 mm ' 2.1 mm ¤Acq-uity 1.7 µm¥ UPLC BEH C-18 column ¤Waters, Milford, MA¥ was used for metabolite separation. The flow rate of the mobile phase was 0.3 ml/min with a gradient ranging from 2% to 98% aqueous acetonitrile containing 0.1% formic acid in a 10-min run. TOFMS ¤SYNAPT HMDS, Waters, Milford, MA¥ was operated in positive mode with electrospray ionization. The source temperature and desolvation temperature were set at 120ôC and 350ôC, respectively. Nitrogen was applied as the cone gas ¤10 L/h¥ and desolvation gas ¤700 L/h¥. Argon was applied as the collision gas. TOFMS was calibrated with sodium formate and monitored by the intermittent injection of lock mass leucine enkephalin in real time. The capillary voltage and cone voltage were set at 3.5 kV and 35 V. Screening and identification of major metabolites and hydrazones were performed by using MetaboLynx and MarkerLynx software ¤Waters, Milford, MA¥ based on accurate mass measurement ¤mass errors less than 10 ppm¥. Tandem mass spectrometry fragmentation was conducted with the collision energy ramp ranging from 10 to 35 eV. Depending on the metabolite, the detection limit of each INH metabolite and hydrazone on column was between 0.05 and 0.5 pmol.
Data analysis: Mass chromatograms and mass spectra were acquired by MassLynx software in centroid format from m/z 50 to m/z 1000. Centroid and integrated mass chromatographic data were processed by MarkerLynx software to generate a multivariate data matrix. The corresponding data matrices were then exported into SIMCA-P¦12 ¤Umetrics, Kinnelon, NJ¥ for multivariate data analysis. Principal component analysis ¤PCA¥ and orthogonal projection to latent structures discriminant analysis ¤OPLS-DA¥ were conducted on Pareto-scaled data.
23¥

Results and Discussion
Metabolic profiles of INH in human urine: The results of metabolomic analysis are shown in Figure 1 and Table 1 . The OPLS-DA score plot ¤Fig. 1A¥ revealed two clusters corresponding to the control and INH-treated groups. The corresponding S-plot ¤Fig. 1B¥ generated from OPLS-DA displays the ion contribution to this group separation. For the MA-derivatized urine samples, the score plot and S-plot are presented in Figures 1C and 1D , respectively. The ions that highly contributed to group separation are INH and its metabolites and hydrazones ¤Figs. 1B and 1D¥. Overall, metabolomic analysis revealed seven novel and eight known metabolites and hydrazones ¤Table 1¥. Among the novel metabolites and hydrazones, two hydroxylated INH metabolites ¤X and XI¥ and five hydrazones ¤XII, XIII, XIV, XV, and XVI¥ were identified. The six healthy subjects exhibited similar INH metabolic profiles, but there were variations in the abundance of each metabolite and hydrazone ¤Supplemental Fig. 2 in Supplemental materials¥.
Identification of hydroxylated INH metabolites: Two hydroxylated INH metabolites ¤X and XI¥ were identified from MA-derivatized human urine samples. The MA-conjugated product of metabolite X ¤eluted at 4.24 min, Fig. 2A¥ had a mass of 272.1038 ¤C 14 H 14 N 3 O 3 ¥, 16 Da higher than that of the MA conjugated product of INH ¤Figs. 2B and 2C¥. X-MA has a similar pattern of MS/MS fragmentation to that of INH-MA. Compared with mass fragments of INH-MA at m/z 123 and 80, X-MA had fragments at m/z 139 and 96, indicating that oxidation occurred on the pyridinyl ring ¤Fig. 2C¥. The metabolite XI-MA was detected at 4.14 min ¤Fig. 2A¥ and had a mass of ªM ¦ H« ¦ © 272.1035 m/z ¤C 14 H 14 N 3 O 3 ¥. The fragments at m/z 139 and 96 suggest that the oxidation took place on the pyridinyl ring ¤Fig. 2D¥. In addition, the structures of metabolite X and XI were confirmed by comparing retention times and mass fragments with the authentic standards.
Role of CYP450 in INH metabolism: In the current study, we examined the role of CYP450s in INH metabolism. No P450-dependent INH metabolite was detected. As for the novel hydroxylated metabolites X and XI, we found that ¤1¥ the generation of metabolite X was NADPH-independent, suggesting that this metabolic pathway is not mediated by CYP450s, and ¤2¥ the generation of metabolite XI was NADPH-dependent ¤data not shown¥, but it was not mediated by CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, or 3A4. Further studies are required to determine the enzyme¤s¥ that contribute to the formation of the two hydroxylated INH metabolites X and XI. INH hepatotoxicity is thought to be dependent on metabolic activation by arylamine N-acetyltransferase and CYP2E1.
24,25¥ In addition, INH toxicity is enhanced during combinational treatment with rifampicin.
26,27¥ Rifampicin is a strong microsomal enzyme inducer; 28¥ thus, it was thought that rifampicin might enhance INH hepatotoxicity via enzymatic induction. 29¥ However, rifampicin does not regulate arylamine N-acetyltransferase or CYP2E1 expression. CYP3A is upregulated by rifampicin via the pregnane X receptor. 28¥ Recently, multiple studies have suggested that CYP3A is involved in INH metabolism and toxicity; 30,31¥ however, CYP3A4-dependent metabolic pathways of INH were not found in the current study.
Identification of INH hydrazones: Several INH hydrazones have been reported; these have been found conjugated with pyruvic acid, AE-ketoglutaric acids, or glucose.
15®19¥ Beyond these reported hydrazones, five novel (1B and 1D) . The number of ions (metabolite identification) was accordant with that in Table 1 . MS/MS of XII produced product ions at m/z 204 ¤loss of HCOOH¥, 123 ¤loss of C 6 H 10 NO 2 ¥, and 80 ¤pyridinyl group¥ ¤Fig. 3B¥. The structure of XII was determined as the hydrazone formed from the conjugation of INH with 4-methyl-2-oxopentanoic acid ¤XIIa¥ and/or 3-methyl-2-oxopentanoic acid ¤XIIb¥. XIII was eluted at 2.81 min ¤Fig. 3A¥ and had a ªM ¦ H« ¦ © 280.0945 m/z ¤C 12 H 14 N 3 O 5 ¥. MS/MS analysis showed product ions at m/z 234 ¤loss of HCOOH¥, 216 ¤loss of HCOOH and H 2 O¥, 123 ¤loss of C 6 H 8 NO 4 ¥, and 80 ¤pyridinyl group¥ ¤Fig. 3C¥. The structure of XIII was determined as the hydrazone formed from the conjugation of INH with 2-oxohexanedioic acid. XIV was detected at 3.09 min ¤Fig. 3A¥ and had a ªM ¦ H« ¦ © 300.0996 m/z ¤C 15 H 14 N 3 O 4 ¥. MS/MS of XIV produced product ions at m/z 254 ¤loss of HCOOH¥, 123 ¤loss of C 9 H 8 NO 2 ¥, and 80 ¤pyridinyl group¥ ¤Fig. 3D¥. The structure of XIV was determined as the hydrazone formed from the conjugation of INH with 3-¤4-hydroxyphenyl¥-2-oxopropanoic acid. XV was eluted at 3.86 min ¤Fig. 3A¥ and had a ªM ¦ H« ¦ © 284.1063 m/z ¤C 15 H 14 N 3 O 3 ¥. The product ions of XV at m/z 238 ¤loss of HCOOH¥, 123 ¤loss of C 9 H 8 NO 2 ¥, and 80 ¤pyridinyl group¥ are interpreted in Figure 3E . The structure of XV was determined as the hydrazone formed from the conjugation of INH with 2-oxo-3-phenylpropanoic acid. XVI ¤eluted at 3.90 min, Fig. 3A¥ had a ªM ¦ H« ¦ © 323.1147 m/z ¤C 17 H 15 N 4 O 3 ¥. MS/MS analysis of XVI showed major product ions at m/z 277 ¤loss of HCOOH¥, 201 ¤loss of C 6 H 5 N 2 O¥, 123 ¤loss of C 11 H 9 N 2 O 2 ¥, and 80 ¤pyridinyl group¥ ¤Fig. 3F¥. The structure of XVI was determined as the hydrazone formed from the conjugation of INH with 3-¤1H-indol-3-yl¥-2-oxopropanoic acid.
4-Methyl-2-oxopentanoic acid and/or 3-methyl-2-oxopentanoic acid, 2-oxohexanedioic acid, 3-¤4-hydroxyphenyl¥-2-oxopropanoic acid, 2-oxo-3-phenylpropanoic acid, and 3-¤1H-indol-3-yl¥-2-oxopropanoic acid are intermediates in the metabolism of essential amino acids, namely, leucine and/or isoleucine, lysine, tyrosine, tryptophan, and phenylalanine. The results of the current study suggest that INH might affect the metabolism of amino acids. In addition, some INH hydrazones have been identified as potent iron chelators 33¥ that may have an effect on iron metabolism and homeostasis. Further studies are needed to investigate the implications of these novel INH hydrazones in INH-induced toxicity.
In summary, INH metabolism was re-investigated in humans using a metabolomic approach, and the map of INH metabolism and disposition was extended with seven novel and eight known pathways ¤Fig. 4¥. In general, this study highlights the power of metabolomics, particularly the combination of UPLC, TOFMS, and multivariate data analysis, to uncover novel drug metabolites. In particular, this study identifies seven novel metabolites and hydrazones of INH that may offer new avenues for investigating INHinduced toxicity.
Fig. 4. INH metabolites and hydrazones in human urine
The map of INH metabolism and disposition was extended with seven novel and eight known pathways by using a metabolomic approach. Eight known INH metabolites and hydrazones were identified as AcINH (I), INA (II), HZ (III), AcHZ (V), isonicotinoyl glycine (IV), and hydrazone derivatives (VII-IX) of glucose, pyruvic acid, and ¡-ketoglutaric acid. Among the novel metabolites and hydrazones, two hydroxylated INH metabolites (X and XI) and five hydrazones (XII, XIII, XIV, XV, and XVI) were identified. Solid arrows: INH metabolites and hydrazones detected by UPLC-TOFMS; Dashed arrows: previously reported or proposed INH metabolites and hydrazones 4, 32) not detected in the current study.
